New drug takes aim at silent liver epidemic
NCT ID NCT04202354
Summary
This early-stage study tested a new drug called ARO-HSD to see if it is safe and how it behaves in the body. It involved 50 healthy volunteers and patients with a serious form of fatty liver disease called NASH. The main goal was to check for side effects and measure how the drug moves through and affects the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Auckland Clinical Studies
Grafton, Auckland, 1010, New Zealand
Conditions
Explore the condition pages connected to this study.